<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-41138" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Systemic Mastocytosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gangireddy</surname>
            <given-names>Mounika</given-names>
          </name>
          <aff>Medstar Franklin Square Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ciofoaia</surname>
            <given-names>Gabriela A.</given-names>
          </name>
          <aff>OSF Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mounika Gangireddy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gabriela Ciofoaia declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-41138.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Systemic mastocytosis is an aggressive disorder characterized by the release of numerous vasoactive cell mediators due to excessive activity of mast cells, which results in a wide variety of symptoms. Symptoms include anaphylaxis, flushing, nonspecific GI as well as neuropsychiatric complaints. This activity outlines the evaluation and management of systemic mastocytosis and reviews the roles of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of systemic mastocytosis.</p></list-item><list-item><p>Review the history, physical, and evaluation of systemic mastocytosis.</p></list-item><list-item><p>Outline the treatment and management options available for systemic mastocytosis.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to enhance the care of patients with systemic mastocytosis and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41138&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41138">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-41138.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Mastocytosis is a constellation of disorders where there are excessive proliferation and accumulation of pathologic mast cells in the tissues. It can involve only skin, which is known as cutaneous mastocytosis, or it can involve extracutaneous tissues which is known as systemic mastocytosis. Cutaneous mastocytosis usually has a benign presentation. Systemic mastocytosis, in particular, is an aggressive form of the disorder characterized by the release of numerous vasoactive cell mediators due to excessive activity of mast cells, which can result in a wide variety of symptoms. The most frequent symptoms associated with the disease include pruritis, flushing, itching, diarrhea, and anaphylaxis.<xref ref-type="bibr" rid="article-41138.r1">[1]</xref><xref ref-type="bibr" rid="article-41138.r2">[2]</xref></p>
      </sec>
      <sec id="article-41138.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Mast cells are immune cells derived from myeloid lineage. They are usually located in the connective tissues. They are activated through immunoglobulin (Ig)E mediated and non-IgE mechanisms and thus act as effector cells in hypersensitivity and allergic reactions.<xref ref-type="bibr" rid="article-41138.r1">[1]</xref> In the IgE mediated mechanism, the allergen forms a cross-link with the IgE receptor, which then activates the mast cells, resulting in degranulation. Non-IgE mediated mechanisms include emotional and physical stimuli, food, drugs like opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), alcohol, heat, exercise, cytokines, venoms, and hormones. The most common mediators released are histamines, proteases, cytokines, growth hormones, tumor necrosis factors, and phospholipases. Tryptases and chymases form an abundant portion of the mast cell granules. Tryptase is almost always secreted by mast cells and therefore it is used as an important diagnostic factor.<xref ref-type="bibr" rid="article-41138.r1">[1]</xref><xref ref-type="bibr" rid="article-41138.r3">[3]</xref><xref ref-type="bibr" rid="article-41138.r4">[4]</xref></p>
      </sec>
      <sec id="article-41138.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Systemic mastocytosis is a rare disorder with unknown incidence. It affects males and females equally.<xref ref-type="bibr" rid="article-41138.r5">[5]</xref> Most of the cases of mastocytosis are limited to the skin, and 80 percent of them appear during childhood. By adolescence, the majority of them improve or resolve completely.<xref ref-type="bibr" rid="article-41138.r6">[6]</xref><xref ref-type="bibr" rid="article-41138.r7">[7]</xref><xref ref-type="bibr" rid="article-41138.r8">[8]</xref> Systemic mastocytosis accounts for more than 95 percent of the adult cases and usually&#x000a0;persists for a longer time.<xref ref-type="bibr" rid="article-41138.r9">[9]</xref></p>
      </sec>
      <sec id="article-41138.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of all types of mastocytosis is the result of chronic and episodic discharge of mast cell mediators and excessive accumulation of mast cells in one or more tissues. Mast cells contain a range of vasoactive mediators and usually operate by releasing these chemicals to produce inflammatory reactions to safeguard the body from microbial invaders and other insults.&#x000a0;The signs and symptoms connected with the sudden and widespread release of the mast cell mediator are comparable to allergic and anaphylactic reactions.</p>
        <p>Mast cell production is under the regulation of a gene named KIT, which encodes CD117 transmembrane tyrosine kinase. CD117 helps in the growth, survival as well as the migration of mast cells. Once the progenitors get produced, they migrate to various tissue and acquire different phenotypes specific to the tissues.&#x000a0;Activating and inactivating mutations of KIT&#x000a0;are implicated in the pathogenesis of systemic mastocytosis.<xref ref-type="bibr" rid="article-41138.r10">[10]</xref><xref ref-type="bibr" rid="article-41138.r11">[11]</xref><xref ref-type="bibr" rid="article-41138.r12">[12]</xref><xref ref-type="bibr" rid="article-41138.r13">[13]</xref>&#x000a0;The precise mechanism by which KIT-activating mutations improve signaling is not thoroughly understood, but these errors lead to stem cell factor (SCF)-independent activation.<xref ref-type="bibr" rid="article-41138.r14">[14]</xref>&#x000a0;KITD816V is the most common driver mutation for systemic mastocytosis.&#x000a0;KIT mutations are mostly somatic, so they don't&#x000a0;seem to be inherited although, they might be present at birth.<xref ref-type="bibr" rid="article-41138.r15">[15]</xref><xref ref-type="bibr" rid="article-41138.r16">[16]</xref> They are rarely present in the germline cells, hence not passed down to the next generation.<xref ref-type="bibr" rid="article-41138.r17">[17]</xref>&#x000a0;FIP1L1-PDGFRA<italic toggle="yes">&#x000a0;</italic>mutation is associated with eosinophilia. Other mutations, namely TET2, IgE, JAK2V617F, and RAS, have associations with systemic mastocytosis as well.</p>
      </sec>
      <sec id="article-41138.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Hematoxylin-eosin stained specimens from bone marrow demonstrate diffuse cohesive or multifocal infiltrates of atypical mast cells or spindle-shaped morphology. Atypical features include immature chromatin or multinucleation.</p>
      </sec>
      <sec id="article-41138.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Systemic mastocytosis involves different organ systems due to the release of vasoactive mediators.&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Episodic mediator release and anaphylaxis&#x000a0;&#x02014;&#x000a0;Acute release of mast cell mediators can result in episodes of vasodilation, hypotension, flushing, pruritus, syncope, abdominal pain, nausea, vomiting, diarrhea, fatigue, and headache.</p>
          </list-item>
          <list-item>
            <p>Anaphylaxis is observable in both cutaneous mastocytosis and systemic mastocytosis. Symptoms typically include flushing, syncope, gastrointestinal symptoms, and vascular collapse. Urticaria and angioedema occur less frequently.<xref ref-type="bibr" rid="article-41138.r18">[18]</xref> These reactions may result from either IgE-mediated allergy or nonspecific activation of mast cells.</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal complaints&#x000a0;&#x02014;&#x000a0;Gastrointestinal dysfunction caused by the release of mast cell mediators is an observation in systemic mastocytosis.<xref ref-type="bibr" rid="article-41138.r19">[19]</xref> Gastrointestinal symptoms can be precipitated by the same triggers that cause systemic symptoms. Signs and symptoms include abdominal pain, diarrhea, nausea, vomiting, peptic ulcer disease, and gastrointestinal bleeding.<xref ref-type="bibr" rid="article-41138.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Neuropsychiatric symptoms&#x000a0;&#x02014;&#x000a0;Neuropsychiatric manifestations, including depression, mood changes, lack of concentration, short memory span, increased somnolence, irritability, as well as emotional instability, are commonly witnessed in adult patients with mastocytosis.<xref ref-type="bibr" rid="article-41138.r21">[21]</xref><xref ref-type="bibr" rid="article-41138.r22">[22]</xref> These symptoms sometimes have the name of "mixed organic brain syndrome."</p>
          </list-item>
          <list-item>
            <p>Musculoskeletal symptoms&#x000a0;&#x02014;&#x000a0;Diffuse musculoskeletal pain of the long bones and a pain syndrome resembling fibromyalgia may appear in patients with systemic mastocytosis.</p>
          </list-item>
          <list-item>
            <p>Osteopenia and osteoporosis&#x000a0;&#x02014;&#x000a0;A subset of patients with systemic mastocytosis appears to be at increased risk of developing osteopenia and osteoporosis.<xref ref-type="bibr" rid="article-41138.r23">[23]</xref><xref ref-type="bibr" rid="article-41138.r24">[24]</xref><xref ref-type="bibr" rid="article-41138.r25">[25]</xref> A bone densitometry measurement is recommended to evaluate for osteoporosis in all patients with systemic mastocytosis.</p>
          </list-item>
          <list-item>
            <p>The most common hematologic abnormality is mild-to-moderate anemia, which occurs in up to 50 percent of patients.<xref ref-type="bibr" rid="article-41138.r26">[26]</xref> Eosinophilia is present in 25 percent of patients.</p>
          </list-item>
          <list-item>
            <p>Peptic ulcer disease, malabsorption, steatorrhea, and liver enlargement commonly present when mast cell infiltration occurs in the intestine or the liver in aggressive systemic mastocytosis (ASM).<xref ref-type="bibr" rid="article-41138.r20">[20]</xref><xref ref-type="bibr" rid="article-41138.r27">[27]</xref><xref ref-type="bibr" rid="article-41138.r28">[28]</xref> Liver function tests may become elevated.</p>
          </list-item>
          <list-item>
            <p>Lymphoid tissues and spleen&#x000a0;&#x02014;&#x000a0;The lymph nodes and spleen commonly have infiltrates in all types of systemic mastocytosis.<xref ref-type="bibr" rid="article-41138.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Central and peripheral lymphadenopathy occurs in 20 to 60 percent of patients with indolent systemic mastocytosis (ISM) and a higher proportion in those with systemic mastocytosis with an associated hematologic neoplasm (SM-AHN), ASM, and mast cell leukemia (MCL).<xref ref-type="bibr" rid="article-41138.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Splenomegaly can present in 50 percent of patients with ISM and over 70 percent of those with SM-AHN, ASM, and MCL.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41138.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Basic Evaluation</bold>
</p>
        <p>The initial evaluation should target establishing the diagnosis and identification of the clonal origin of the disease. At diagnosis, a complete medical history is necessary. A comprehensive symptomatic assessment is pertinent, and triggers of mast cell activation symptoms require documentation (NSAIDs, heat, opioids, anesthetics, friction, contrast, anxiety, stress, vaccines, dextrans, and insect bites). Note any previous history of anaphylaxis to any particular food, medications, or other triggers requiring epinephrine.<xref ref-type="bibr" rid="article-41138.r2">[2]</xref></p>
        <p>
<bold>Includes the following workup:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Laboratory evaluation includes a complete blood count, renal and hepatic function panel, serum tryptase, albumin, and calcium.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Bone marrow aspiration and biopsy should have immunophenotyping for CD25, tryptase, and KIT mutations.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Bone densitometry is a recommendation as systemic mastocytosis patients are at increased risk for bone loss.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Advanced Evaluation</bold>
</p>
        <p>Based on the clinical presentation, the following additional studies are performed:</p>
        <list list-type="bullet">
          <list-item>
            <p>Abdominal computed tomography (CT) scan is indicated for abnormal white blood cell counts, hepatosplenomegaly, or lymphadenopathy.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal endoscopy and biopsies are indicated for patients with GI symptoms.</p>
          </list-item>
          <list-item>
            <p>Biopsies of liver and lymph nodes are indicated with the elevation of liver function tests or if patients experience any localizing symptoms, respectively.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Criteria for diagnosis of Systemic Mastocytosis:</bold><xref ref-type="bibr" rid="article-41138.r4">[4]</xref><bold>&#x000a0;</bold> As per the World Health Organization (WHO) diagnostic criteria for systemic mastocytosis:</p>
        <p>1. Major criterion:</p>
        <list list-type="bullet">
          <list-item>
            <p>Presence of multifocal clusters of abnormal mast cells (greater than 15% of mast cells in clusters) in the bone marrow or extracutaneous tissues.&#x000a0;</p>
          </list-item>
        </list>
        <p>2. Minor criterion:</p>
        <list list-type="bullet">
          <list-item>
            <p>Elevated serum tryptase level (over 20 ng/ml)</p>
          </list-item>
          <list-item>
            <p>Abnormal mast cell CD25 expression</p>
          </list-item>
          <list-item>
            <p>Presence of KITD 816V mutation</p>
          </list-item>
          <list-item>
            <p>Presence of greater than 25% atypical mast cells.&#x000a0;</p>
          </list-item>
        </list>
        <p>Diagnosis of systemic mastocytosis requires one major and one minor criterion or three minor criteria.</p>
        <p><bold>Evaluation for Organ Dysfunction:</bold> It consists of B and C findings.<xref ref-type="bibr" rid="article-41138.r4">[4]</xref></p>
        <p>B findings include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bone marrow biopsy over 30% of mast cells or abnormally high serum tryptases</p>
          </list-item>
          <list-item>
            <p>Hepatomegaly or splenomegaly or lymphadenopathy</p>
          </list-item>
        </list>
        <p>C findings include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Bone marrow biopsy shows cytopenias&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Palpable hepatomegaly as well splenomegaly&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Osteolytic lesions or pathologic fractures</p>
          </list-item>
          <list-item>
            <p>Malabsorption resulting from mast cell infiltration of the GI tract</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41138.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management for systemic mastocytosis has its basis in symptoms and subtypes.<xref ref-type="bibr" rid="article-41138.r4">[4]</xref></p>
        <p>
<bold>Symptom Specific Management</bold>
</p>
        <p>The following therapies may be necessary for symptomatic patients with any subtype of systemic mastocytosis (SM).&#x000a0;</p>
        <p><bold>Antihistamines</bold>&#x000a0;&#x02014;&#x000a0;Initial pharmacologic treatment includes the use of H1 and H2 antihistamines. H1 antihistamines are administered to prevent flushing and itching. H2 antihistamines may help with abdominal pain, heartburn, cramping, and/or diarrhea.</p>
        <p><bold>Antileukotriene drugs</bold>&#x000a0;&#x02014;&#x000a0;Antileukotriene agents may be an option in patients with flushing, itching, or abdominal cramping unresponsive to H1 and H2 antihistamines.<xref ref-type="bibr" rid="article-41138.r31">[31]</xref></p>
        <p><bold>Recurrent anaphylaxis</bold>&#x000a0;&#x02014;&#x000a0;For patients with systemic mastocytosis who experience recurrent anaphylaxis or mast cell activation symptoms with hemodynamic instability despite trigger avoidance, maximized doses of anti-mediator agents (H1 and H2 antihistamines and anti-leukotriene drugs) may provide benefit. These patients should also have injectable epinephrine with them at all times.</p>
        <p><bold>Omalizumab</bold>&#x000a0;&#x02014; Omalizumab&#x000a0;(anti-IgE), a humanized monoclonal antibody that inhibits the binding of IgE to mast cells, reduced the frequency of anaphylaxis in a few patients with SM or monoclonal mast cell activation syndrome.<xref ref-type="bibr" rid="article-41138.r32">[32]</xref><xref ref-type="bibr" rid="article-41138.r33">[33]</xref></p>
        <p><bold>Flushing</bold>&#x000a0;&#x02014;&#x000a0;In patients with prominent flushing not responsive to antihistamines, aspirin may be helpful, provided the patient is known to tolerate NSAIDs.<xref ref-type="bibr" rid="article-41138.r34">[34]</xref></p>
        <p><bold>Gastrointestinal symptoms&#x000a0;</bold>&#x02014;&#x000a0;Gastrointestinal symptoms in patients with systemic mastocytosis may respond to oral cromolyn sodium, H2 antihistamines, and proton pump inhibitors (PPIs). Orally administered glucocorticoids are helpful for patients with aggressive systemic mastocytosis (ASM) and severe malabsorption or ascites.<xref ref-type="bibr" rid="article-41138.r35">[35]</xref></p>
        <p><bold>Osteoporosis and fractures</bold>&#x000a0;&#x02014;&#x000a0;Appropriate daily intake of calcium and vitamin D should be maintained. For patients with osteoporosis-related fractures, treatment with the combination of pamidronate&#x000a0;and low-dose interferon-alfa has been reported to be helpful.<xref ref-type="bibr" rid="article-41138.r36">[36]</xref></p>
        <p><bold>Refractory symptoms -&#x000a0;</bold>In patients who are unresponsive to anti-mediator therapies and omalizumab, low-dose maintenance glucocorticoids or cytoreductive measures (such as interferon-alfa, cladribine, or a tyrosine kinase inhibitor [TKI] depending on KIT mutational status) can be considered as second-line approaches.</p>
        <p>
<bold>Subtype-specific Management</bold>
</p>
        <p><bold>Indolent </bold><bold>Systemic Mastocytosis or Smoldering S</bold><bold>ystemic Mastocytosis:</bold>&#x000a0;Treatment with cytoreductive therapy is also appropriate for select patients with ISM or smoldering systemic mastocytosis (SSM) who suffer from recurrent anaphylaxis that remains uncontrolled with anti-mediator treatments, although this is only appropriate when all other options have been exhausted.<xref ref-type="bibr" rid="article-41138.r37">[37]</xref></p>
        <p><bold>Aggressive SM: </bold>Management of aggressive forms of systemic mastocytosis is with cladribine, midostaurin, interferon-alpha, or TKI inhibitors (imatinib) based on mutation status along with bone marrow transplant. Treatment of advanced systemic mastocytosis is indicated to mitigate organ dysfunction and improve the quality of life. For those patients eligible for hematopoietic cell transplantation (HCT), the goal is to control symptoms and prevent progression until a donor can be found.</p>
        <p><bold>SM-AHN: </bold>Treatment in this subtype focuses on the associated hematopoietic disorder. After the initial salvage therapy, HCT should be a consideration for maintenance.<xref ref-type="bibr" rid="article-41138.r4">[4]</xref></p>
        <p><bold>Mast cell Leukemia:</bold> There is no standard treatment to treat mast cell leukemia. It has a poor prognosis overall.&#x000a0;</p>
        <p>In patients with venom allergy, treatment with venom immunotherapy is helpful to reduce further episodes of anaphylaxis.</p>
      </sec>
      <sec id="article-41138.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>&#x000a0;Differentials are broad for systemic mastocytosis.</p>
        <list list-type="bullet">
          <list-item>
            <p>Carcinoid syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>VIPoma</p>
          </list-item>
          <list-item>
            <p>Zollinger-Ellison syndrome</p>
          </list-item>
          <list-item>
            <p>Acute urticaria</p>
          </list-item>
          <list-item>
            <p>Inflammatory bowel&#x000a0;disease</p>
          </list-item>
          <list-item>
            <p>Irritable&#x000a0;bowel syndrome</p>
          </list-item>
          <list-item>
            <p>Malabsorption</p>
          </list-item>
          <list-item>
            <p>Myeloproliferative disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41138.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Numerous drugs are undergoing clinical trial investigations. Mammalian target of rapamycin (mTOR) and phosphatidylinositol 3 kinase (PI3K) target downstream KIT signaling. A study evaluating the effect of multi-kinase inhibitor DCC-2618 on proliferation indicated a promising result that the agent can reduce the proliferation and survival of neoplastic mast cells. Therefore it can play a role in advanced systemic mastocytosis.<xref ref-type="bibr" rid="article-41138.r2">[2]</xref></p>
      </sec>
      <sec id="article-41138.s12" sec-type="Staging">
        <title>Staging</title>
        <p>WHO (World Health Organization) classification of systemic mastocytosis include:<xref ref-type="bibr" rid="article-41138.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Indolent systemic mastocytosis (ISM)</p>
          </list-item>
          <list-item>
            <p>Smoldering systemic mastocytosis (SSM)</p>
          </list-item>
          <list-item>
            <p>Aggressive systemic mastocytosis (ASM)</p>
          </list-item>
          <list-item>
            <p>Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN)</p>
          </list-item>
          <list-item>
            <p>Mast cell leukemia (MCL)</p>
          </list-item>
        </list>
        <p>SM-AHN subtype subclassifies into:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>SM with acute myeloid leukemia</p>
          </list-item>
          <list-item>
            <p>SM with myelodysplastic syndrome</p>
          </list-item>
          <list-item>
            <p>SM with a myeloproliferative disorder</p>
          </list-item>
          <list-item>
            <p>SM with chronic myelomonocytic leukemia</p>
          </list-item>
          <list-item>
            <p>SM with hypereosinophilic syndrome</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41138.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The disease subtype is one of the strongest prognostic predictors in systemic mastocytosis.</p>
        <p>Certain clinical features are associated with an increased risk of death due to disease progression, independent of the category of systemic mastocytosis present. These features include the following:<xref ref-type="bibr" rid="article-41138.r1">[1]</xref><xref ref-type="bibr" rid="article-41138.r38">[38]</xref><xref ref-type="bibr" rid="article-41138.r39">[39]</xref><xref ref-type="bibr" rid="article-41138.r40">[40]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Low platelet count (less than 150&#x000a0;&#x000d7;&#x000a0;10/l)</p>
          </list-item>
          <list-item>
            <p>Low serum albumin (under 35&#x000a0;g/L)</p>
          </list-item>
          <list-item>
            <p>Low hemoglobin levels (less than 100&#x000a0;g/L or red blood cell transfusion dependence)</p>
          </list-item>
          <list-item>
            <p>Elevated lactate dehydrogenase (LDH)</p>
          </list-item>
          <list-item>
            <p>Older age at onset of systemic symptoms (age over 60)</p>
          </list-item>
          <list-item>
            <p>High alkaline phosphatase</p>
          </list-item>
          <list-item>
            <p>Hepatosplenomegaly&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ascites&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Excess bone marrow blasts</p>
          </list-item>
          <list-item>
            <p>Weight loss</p>
          </list-item>
          <list-item>
            <p>ASXL1 mutation</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41138.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Systemic mastocytosis is associated with many disorders, such as:</p>
        <list list-type="order">
          <list-item>
            <p>Monoclonal gammopathy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hairy cell leukemia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Non-Hodgkin lymphoma</p>
          </list-item>
          <list-item>
            <p>Polycythemia vera&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Primary thrombocythemia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Anemia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatosplenomegaly&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypereosinophilic syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Castleman syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Coagulopathy</p>
          </list-item>
          <list-item>
            <p>Recurrent anaphylaxis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41138.s15" sec-type="Consultations">
        <title>Consultations</title>
        <p>Newly diagnosed patients with systemic mastocytosis need the following consultants:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hematologist&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dermatologist</p>
          </list-item>
          <list-item>
            <p>Immunologist&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Gastroenterologist</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-41138.s16" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>All patients with mastocytosis should carry epinephrine-filled syringes at all times and should receive education regarding the administration of epinephrine in cases of emergency. They should understand the avoidance of triggers such as exposure to heat or cold, medications such as aspirin, strenuous activity, alcohol, spicy foods, anesthesia, surgery, or endoscopy. Clinicians need to administer premedications before any surgery, minor procedures, or radiocontrast dye to avoid anaphylaxis. Premedications include diphenhydramine, ranitidine, montelukast, and prednisone. Insect stings (<italic toggle="yes">Hymenoptera</italic>) could also precipitate anaphylaxis in patients who developed IgE-mediated sensitivity. Patients should have testing for venom allergy and, if positive, should be treated with venom immunotherapy to decrease subsequent anaphylaxis to insect stings.<xref ref-type="bibr" rid="article-41138.r41">[41]</xref><xref ref-type="bibr" rid="article-41138.r42">[42]</xref><xref ref-type="bibr" rid="article-41138.r43">[43]</xref></p>
      </sec>
      <sec id="article-41138.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The unique clinical profile of systemic mastocytosis combined with diagnostic and pharmacological advancements poses a challenge for many clinicians; thus, an interprofessional approach is necessary.</p>
        <p>Primary care clinicians should obtain a detailed history as well as a physical evaluation of the patient with recurrent allergies. If systemic mastocytosis is suspected, referral to an immunologist, and hematologist is recommended.</p>
        <p>Close coordination of care amongst allergists, immunologists as well as hematologists is crucial to prevent any delay in diagnosis and management.</p>
        <p>Clinicians, including nursing staff and pharmacists, play an essential role in identifying symptoms of anaphylaxis and the immediate administration of epinephrine. The pharmacist should educate the patient about the importance of epinephrine. Pharmacists also need to reconcile medications for possible drug interactions, as well as verifying dosing, and report any concerns to nursing or the managing clinician. Nursing can monitor medication compliance, and also report any potential adverse effects to the physician or the pharmacist. This collaborative approach between members of the interprofessional healthcare team is essential for optimal patient outcomes. [Level 5]</p>
        <p>The patient should be told to wear an ID bracelet, which reveals his or her medical condition. They should be educated about avoidance of triggers such as exposure to heat or cold, medications such as aspirin, strenuous activity, alcohol, spicy foods, anesthesia, surgery, or endoscopy.&#x000a0;</p>
        <p>Patients with systemic mastocytosis should undergo next-generation sequencing (NGS) to identify potential genetic carriers, which might predispose them to a poor prognosis. NGS is very new and is underutilized. Patients with uncontrolled symptoms, diagnostic difficulties, and advanced disease should obtain a referral to centers that specialize in mast cell disorders in the advent of multiple clinical trials. [Level 5]</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>The outcomes of patients with systemic mastocytosis are guarded, and the quality of life is poor. The symptoms can come on at any time and lead to severe distress; hence, most patients have a restricted lifestyle. For those with more severe disease, the outcomes are the worst.<xref ref-type="bibr" rid="article-41138.r44">[44]</xref> [Level 5]</p>
      </sec>
      <sec id="article-41138.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=41138&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=41138">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/systemic-mastocytosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=41138">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/41138/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=41138">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-41138.s19">
        <title>References</title>
        <ref id="article-41138.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malone</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Curci</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Mastocytosis.</article-title>
            <source>Prim Care</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>505</fpage>
            <page-range>505-18</page-range>
            <pub-id pub-id-type="pmid">27545739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scherber</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Borate</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>How we diagnose and treat systemic mastocytosis in adults.</article-title>
            <source>Br J Haematol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>180</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-23</page-range>
            <pub-id pub-id-type="pmid">29048112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krystel-Whittemore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dileepan</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Mast Cell: A Multi-Functional Master Cell.</article-title>
            <source>Front Immunol</source>
            <year>2015</year>
            <volume>6</volume>
            <fpage>620</fpage>
            <pub-id pub-id-type="pmid">26779180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pardanani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.</article-title>
            <source>Am J Hematol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>94</volume>
            <issue>3</issue>
            <fpage>363</fpage>
            <page-range>363-377</page-range>
            <pub-id pub-id-type="pmid">30536695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000e9;ni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bruneau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Georgin-Lavialle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Le Sach&#x000e9; de Peufeilhoux</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Damaj</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hadj-Rabia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fraitag</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dubreuil</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bodemer</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Paediatric mastocytosis: a systematic review of 1747 cases.</article-title>
            <source>Br J Dermatol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>172</volume>
            <issue>3</issue>
            <fpage>642</fpage>
            <page-range>642-51</page-range>
            <pub-id pub-id-type="pmid">25662299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirshenbaum</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Kettelhut</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Garriga</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Mastocytosis in infants and children: recognition of patterns of skin disease.</article-title>
            <source>Allergy Proc</source>
            <year>1989</year>
            <season>Jan-Feb</season>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-21</page-range>
            <pub-id pub-id-type="pmid">2925086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kettelhut</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Hematopathology of the bone marrow in pediatric cutaneous mastocytosis. A study of 17 patients.</article-title>
            <source>Am J Clin Pathol</source>
            <year>1989</year>
            <month>May</month>
            <volume>91</volume>
            <issue>5</issue>
            <fpage>558</fpage>
            <page-range>558-62</page-range>
            <pub-id pub-id-type="pmid">2470248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akoglu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Erkin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cakir</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Boztepe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sahin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karaduman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Atakan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Akan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kolemen</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous mastocytosis: demographic aspects and clinical features of 55 patients.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>969</fpage>
            <page-range>969-73</page-range>
            <pub-id pub-id-type="pmid">16922947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Komar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petzelbauer</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical and histopathological aspects of cutaneous mastocytosis.</article-title>
            <source>Leuk Res</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>519</fpage>
            <page-range>519-28</page-range>
            <pub-id pub-id-type="pmid">11377676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valent</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sperr</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Horny</surname>
                <given-names>HP</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>114</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-11; quiz 12</page-range>
            <pub-id pub-id-type="pmid">15241337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galli</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wershil</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others.</article-title>
            <source>Am J Pathol</source>
            <year>1993</year>
            <month>Apr</month>
            <volume>142</volume>
            <issue>4</issue>
            <fpage>965</fpage>
            <page-range>965-74</page-range>
            <pub-id pub-id-type="pmid">7682764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furitsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsujimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kitayama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Koshimizu</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sugahara</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Butterfield</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ashman</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Kanayama</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.</article-title>
            <source>J Clin Invest</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>92</volume>
            <issue>4</issue>
            <fpage>1736</fpage>
            <page-range>1736-44</page-range>
            <pub-id pub-id-type="pmid">7691885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.</article-title>
            <source>J Mol Diagn</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>412</fpage>
            <page-range>412-9</page-range>
            <pub-id pub-id-type="pmid">16931579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Kit signal transduction.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>517</fpage>
            <page-range>517-35</page-range>
            <pub-id pub-id-type="pmid">10909038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longley</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Tharp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tyrrell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Heitjan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1999</year>
            <month>Feb</month>
            <day>16</day>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>1609</fpage>
            <page-range>1609-14</page-range>
            <pub-id pub-id-type="pmid">9990072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reilly</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Class III receptor tyrosine kinases: role in leukaemogenesis.</article-title>
            <source>Br J Haematol</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>116</volume>
            <issue>4</issue>
            <fpage>744</fpage>
            <page-range>744-57</page-range>
            <pub-id pub-id-type="pmid">11886377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yavuz</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Lipsky</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Yavuz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Akin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene.</article-title>
            <source>Blood</source>
            <year>2002</year>
            <month>Jul</month>
            <day>15</day>
            <volume>100</volume>
            <issue>2</issue>
            <fpage>661</fpage>
            <page-range>661-5</page-range>
            <pub-id pub-id-type="pmid">12091362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lavigne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chappard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verret</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chevailler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nicolie</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Drouet</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase.</article-title>
            <source>Clin Exp Allergy</source>
            <year>2009</year>
            <month>May</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>717</fpage>
            <page-range>717-25</page-range>
            <pub-id pub-id-type="pmid">19302252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal abnormalities and involvement in systemic mastocytosis.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>579</fpage>
            <page-range>579-623</page-range>
            <pub-id pub-id-type="pmid">10909042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sokol</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Georgin-Lavialle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Canioni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barete</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Damaj</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Soucie</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bruneau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chandesris</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Launay</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Aouba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grandpeix-Guyodo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lanternier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grosbois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>de Gennes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cath&#x000e9;bras</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fain</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hoyeau-Idrissi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dubreuil</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lortholary</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Beaugerie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ranque</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal manifestations in mastocytosis: a study of 83 patients.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>132</volume>
            <issue>4</issue>
            <fpage>866</fpage>
            <page-range>866-73.e1-3</page-range>
            <pub-id pub-id-type="pmid">23890756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horan</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Austen</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital.</article-title>
            <source>J Invest Dermatol</source>
            <year>1991</year>
            <month>Mar</month>
            <volume>96</volume>
            <issue>3</issue>
            <fpage>5S</fpage>
            <page-range>5S-13S; discussion 13S-14S</page-range>
            <pub-id pub-id-type="pmid">2002264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moura</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Georgin-Lavialle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gaillard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Neuropsychological features of adult mastocytosis.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2014</year>
            <month>May</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>407</fpage>
            <page-range>407-22</page-range>
            <pub-id pub-id-type="pmid">24745683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kushnir-Sukhov</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Brittain</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Akin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis.</article-title>
            <source>Int Arch Allergy Immunol</source>
            <year>2006</year>
            <volume>139</volume>
            <issue>3</issue>
            <fpage>265</fpage>
            <page-range>265-70</page-range>
            <pub-id pub-id-type="pmid">16449817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Veer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van der Goot</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>de Monchy</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Kluin-Nelemans</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>van Doormaal</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis.</article-title>
            <source>Allergy</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>3</issue>
            <fpage>431</fpage>
            <page-range>431-8</page-range>
            <pub-id pub-id-type="pmid">22229787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barete</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Assous</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>de Gennes</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grandpeix</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Feger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Palmerini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dubreuil</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Arock</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Launay</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fraitag</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Canioni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Billemont</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lanternier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lortholary</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Franc&#x000e8;s</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Systemic mastocytosis and bone involvement in a cohort of 75 patients.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>69</volume>
            <issue>10</issue>
            <fpage>1838</fpage>
            <page-range>1838-41</page-range>
            <pub-id pub-id-type="pmid">20570833</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lawrence</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Chinchilli</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Gralnick</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis.</article-title>
            <source>Am J Med</source>
            <year>1991</year>
            <month>Dec</month>
            <volume>91</volume>
            <issue>6</issue>
            <fpage>612</fpage>
            <page-range>612-24</page-range>
            <pub-id pub-id-type="pmid">1750431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castells</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Friend</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Bunnell</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Osteen</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Austen</surname>
                <given-names>KF</given-names>
              </name>
            </person-group>
            <article-title>The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>98</volume>
            <issue>4</issue>
            <fpage>831</fpage>
            <page-range>831-40</page-range>
            <pub-id pub-id-type="pmid">8876560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reisberg</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Oyakawa</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mastocytosis with malabsorption, myelofibrosis, and massive ascites.</article-title>
            <source>Am J Gastroenterol</source>
            <year>1987</year>
            <month>Jan</month>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-60</page-range>
            <pub-id pub-id-type="pmid">3799581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mekori</surname>
                <given-names>YA</given-names>
              </name>
            </person-group>
            <article-title>Lymphoid tissues and the immune system in mastocytosis.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>569</fpage>
            <page-range>569-77</page-range>
            <pub-id pub-id-type="pmid">10909041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Travis</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Pathology of the lymph node and spleen in systemic mast cell disease.</article-title>
            <source>Mod Pathol</source>
            <year>1988</year>
            <month>Jan</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-14</page-range>
            <pub-id pub-id-type="pmid">3237690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tolar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tope</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Neglia</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Leukotriene-receptor inhibition for the treatment of systemic mastocytosis.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Feb</month>
            <day>12</day>
            <volume>350</volume>
            <issue>7</issue>
            <fpage>735</fpage>
            <page-range>735-6</page-range>
            <pub-id pub-id-type="pmid">14960756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carter</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Robyn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>119</volume>
            <issue>6</issue>
            <fpage>1550</fpage>
            <page-range>1550-1</page-range>
            <pub-id pub-id-type="pmid">17481708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jagdis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vadas</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>113</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-6</page-range>
            <pub-id pub-id-type="pmid">24950847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Worobec</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Treatment of systemic mast cell disorders.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>659</fpage>
            <page-range>659-87, vii</page-range>
            <pub-id pub-id-type="pmid">10909045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valent</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sperr</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Akin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>How I treat patients with advanced systemic mastocytosis.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Dec</month>
            <day>23</day>
            <volume>116</volume>
            <issue>26</issue>
            <fpage>5812</fpage>
            <page-range>5812-7</page-range>
            <pub-id pub-id-type="pmid">20855864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laroche</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Livideanu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cantagrel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis.</article-title>
            <source>Am J Med</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>124</volume>
            <issue>8</issue>
            <fpage>776</fpage>
            <page-range>776-8</page-range>
            <pub-id pub-id-type="pmid">21787907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barete</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lortholary</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Damaj</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chandesris</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Elie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hamidou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Durieu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grosbois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Limal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gyan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Larroche</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guillet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Casassus</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Amazzough</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Coignard-Biehler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Georgin-Lavialle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lhermitte</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fraitag</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Canioni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dubreuil</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis.</article-title>
            <source>Blood</source>
            <year>2015</year>
            <month>Aug</month>
            <day>20</day>
            <volume>126</volume>
            <issue>8</issue>
            <fpage>1009</fpage>
            <page-range>1009-16; quiz 1050</page-range>
            <pub-id pub-id-type="pmid">26002962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lasho</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Finke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patnaik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Butterfield</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>McClure</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Pardanani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Jun</month>
            <day>04</day>
            <volume>113</volume>
            <issue>23</issue>
            <fpage>5727</fpage>
            <page-range>5727-36</page-range>
            <pub-id pub-id-type="pmid">19363219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pardanani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.</article-title>
            <source>Am J Hematol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>250</fpage>
            <page-range>250-62</page-range>
            <pub-id pub-id-type="pmid">25688753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pardanani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.</article-title>
            <source>Am J Hematol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>91</volume>
            <issue>11</issue>
            <fpage>1146</fpage>
            <page-range>1146-1159</page-range>
            <pub-id pub-id-type="pmid">27762455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brockow</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jofer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Behrendt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ring</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.</article-title>
            <source>Allergy</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>226</fpage>
            <page-range>226-32</page-range>
            <pub-id pub-id-type="pmid">18186813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez de Olano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>de la Hoz Caballer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>N&#x000fa;&#x000f1;ez L&#x000f3;pez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez Mu&#x000f1;oz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cuevas Agust&#x000ed;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di&#x000e9;guez</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Alvarez Twose</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Castells</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Escribano Mora</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA).</article-title>
            <source>Clin Exp Allergy</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>1547</fpage>
            <page-range>1547-55</page-range>
            <pub-id pub-id-type="pmid">17883734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis and mast cell disease: what is the risk?</article-title>
            <source>Curr Allergy Asthma Rep</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-8</page-range>
            <pub-id pub-id-type="pmid">20425512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-41138.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Budnik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>A registry-based analysis of survival outcomes in mast cell leukemia.</article-title>
            <source>Leuk Res</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>78</volume>
            <fpage>24</fpage>
            <page-range>24-28</page-range>
            <pub-id pub-id-type="pmid">30665051</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
